Exorcising ghostwriting. Ghostwriting could potentially have serious repercussions for science and should therefore be treated as research misconduct

EMBO Reports

Volumn 12, Issue 6, 2011, Pages 489-494

  Bosch, Xavier ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FENFLURAMINE; PHENTERMINE; RANIBIZUMAB; ROFECOXIB;

ARTICLE; BREAST CANCER; CANCER RISK; DEMENTIA; DRUG COST; DRUG INDUSTRY; EDITOR; FUNDING; GHOSTWRITING; GOVERNMENT; LAW SUIT; MEDICAL RESEARCH; MEDICARE; PARKINSON DISEASE; POLICY; PRIORITY JOURNAL; PUBLIC FIGURE; PUBLIC HEALTH; PUBLICATION; WRITING;

AUTHORSHIP; BIOMEDICAL RESEARCH; HUMANS; PERIODICALS AS TOPIC; SCIENTIFIC MISCONDUCT;

EID: 79957992492     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.1038/embor.2011.87     Document Type: Article

References (32)

1. Anekwe tD (2010) profits and plagiarism: the case of medical ghostwriting. Bioethics 24: 267-272
2. Barbour V (2010) How ghost-writing threatens the credibility of medical knowledge and medical journals. Haematologica 95: 1-2
3. Bosch X (2010) Safeguarding good scientific practice in Europe. EMBO Rep 11: 252-257
4. C-Span (2009) Newsmakers with Dr. Francis Collins. Washington DC, USa: c-Span. http:// www.c-spanarchives.org/program/290855-1
5. Danish Ministry of Science, Technology and innovation (2005) Bekendtgørelse om udvalgene vedrørende videnskabelig uredelighed 2005. https://www.retsinformation.dk/Forms/ r0710.aspx?id=29238
6. Daskalopoulou SS, Mikhailidis Dp (2005) the involvement of professional medical writers in medical publications. Curr Med Res Opin 21: 307-310
7. Dunbar CE, Tallman MS (2009) 'ghostbusting' at blood. Blood 113: 502-503
8. ESF (2010) Member Organization Forum. Fostering Research Integrity in Europe. Executive report. Strasbourg, France: European Science Foundation. http://www.esf.org/ activities/mo-fora/publications.html
9. Flanagin A et al (1998) prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA 280: 222-224 (Pubitemid 28493887)
10. Fugh-Berman aJ (2010) the haunting of medical journals: how ghostwriting sold "Hrt". PLoS Med 7: e1000335
11. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan aW (2007) ghost authorship in industry-initiated randomised trials. PLoS Med 4: e19
12. Gøtzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, Gertel A (2009) What should be done to tackle ghostwriting in the medical literature? PLoS Med 6: e23
13. Grassley (2010) Senator charles grassley letter to Francis S collins. http://grassley.senate.gov/ about/upload/2010-06-24-letter-to-niH.pdf
14. HHS (2010) Responsibility of Applicants for Promoting Objectivity in Research for Which Public Health Service Funding Is Sought and Responsible Prospective Contractors; Proposed Rule. Federal register 75, no. 98
15. IcMJE (2008) Uniform requirements for manuscripts submitted to biomedical journals. international committee of Medical Journal Editors. www.icmje.org
16. Institute of Medicine (2009) Conflict of Interest in Medical Research, Education, And Practice. Washington DC, USa: institute of Medicine http://books.nap.edu/openbook.php?record-id=12598
17. Jacobs A, Wager E (2005) European Medical Writers association (EMWa) guidelines on the role of medical writers in developing peer-reviewed publications. Curr Med Res Opin 21: 317-322
18. Krimsky S (2007) When conflict-of-interest is a factor in scientific misconduct. Med Law 26: 447-463 (Pubitemid 47629170)
19. Lacasse JR, Leo J (2010) ghostwriting at elite academic medical centers in the united States. PLoS Med 7: e1000230
20. Landow L (2002) Sponsorship, Authorship, And accountability. N Engl J Med 346: 290-292
21. Morrissey A (2010) Manipulation of prescription drug research data: merely an ethical breach or a fraudulent claim? ABA Health eSource 6: Jan [online]
22. Pear R (2009) in house, Many spoke with one voice: lobbyists. New York Times nov 14
23. Pharmaceutical research and Manufacturers of america (2009) Principles on Conduct of Clinical Trials. Communication of Clinical Trial Results. http://www.phrma.org/sites/default/ files/800/042009-clinical-trial-principles- final.pdf ploS
24. Medicine Editors (2009) Ghostwriting: the dirty little secret of medical publishing that just got bigger. PLoS Med 6: e1000156
25. Rockey SJ, Collins FS (2010) Managing financial conflict of interest in biomedical research. JAMA 303: 2400-2402
26. Ross JS, Hill KP, Egilman DS, Krumholz HM (2008) guest authorship and ghostwriting in publications related to rofecoxib. A case study of industry documents from rofecoxib litigation. JAMA 299: 1800-1812 (Pubitemid 351549971)
27. Singer N, Wilson D (2009) Medical editors push for ghostwriting crackdown. New York Times Sep 17
28. The Danish committees on Scientific Dishonesty (2003) Annual Report. copenhagen, Denmark: Danish agency for Science, Technology and innovation
29. Titus S, Bosch X (2010) tie funding to research integrity. Nature 466: 436-437
30. Wager E (2007) authors, Ghosts, Damned lies, And statisticians. PLoS Med 4: e34
31. WaME (2005) Ghost writing initiated by commercial companies. toronto, Canada: World association of Medical Editors. http:// www.wame.org/resources/ policies#ghost
32. Wislar J, Flanagin A, Fontanarosa PB, Deangelis cD (2009) Prevalence of Honorary and Ghost Authorship in 6 General Medical Journals. Sixth international congress on peer review and Biomedical publication. 10-12 September. Vancouver, Canada